Prophylactic Mesh Reinforcement Versus Primary Closure After Emergency Midline Laparotomy (PREEMPT)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Rome Tor Vergata

About this trial

The PREEMPT trial is a multicenter randomized controlled trial comparing prophylactic onlay biosynthetic mesh reinforcement with primary suture closure in adult patients undergoing emergency midline laparotomy. Participants will be randomized in a 1:1 ratio. The primary endpoint is the incidence of incisional hernia at 1 year. Secondary endpoints include postoperative complications, surgical site occurrences, pain, operative time, hospital stay, morbidity, mortality, quality of life, and long-term hernia incidence.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Age < 18 years

Minimally invasive surgery (laparoscopic or robotic approaches)

Elective surgery

Surgery requiring an open abdomen and its closure

Trial design

Design model

Parallel

Treatments tested in this trial

  • Prophylactic Biosynthetic Mesh Placement

    Device

    A biosynthetic mesh (poly-4-hydroxybutyrate mesh) is placed prophylactically to reinforce abdominal wall closure during laparotomy closure.

  • Direct suture

    Procedure/Surgery

    Direct fascial suture closure of the abdominal wall after laparotomy without prophylactic mesh reinforcement.

Treatment groups

189 Participants
are divided into 2 treatment groups
Group A: Mesh-repair groupExperimental treatment 1 intervention
Group B: Direct suture groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of incisional hernia at 12 months after laparotomy

The primary outcome is the occurrence of incisional hernia within 12 months after laparotomy, assessed by clinical examination and/or imaging according to the study protocol. The incidence of incisional hernia will be compared between patients receiving prophylactic biosynthetic mesh reinforcement and patients undergoing standard abdominal wall closure without mesh.

Time frame
12 months after laparotomy

Secondary outcomes

1

Postoperative complications

Postoperative complications will be assessed according to the Clavien-Dindo classification.

Time frame
Within 30 days after surgery
2

Incidence of surgical site infection

The incidence of surgical site infection (superficial, deep, and organ-space infection) occurring after laparotomy will be evaluated and compared between treatment groups

Time frame
Within 30 days after surgery
3

Incidence of surgical site occurrences after emergency laparotomy

The incidence of surgical site occurrences (SSO), including surgical site infection, seroma, wound dehiscence, hematoma, and other wound-related complications, will be assessed and compared between treatment groups.

Time frame
Within 30 days after surgery
4

Incidence of surgical site occurrences requiring procedural intervention (SSOPI)

The incidence of surgical site occurrences requiring procedural intervention (SSOPI) will be assessed. SSOPI include surgical site occurrences requiring invasive treatment, such as wound drainage, percutaneous intervention, surgical debridement, or other procedural management.

Time frame
Within 30 days after surgery

Other outcomes

1

Operative time

Operative time will be measured from skin incision to completion of skin closure and compared between patients undergoing prophylactic biosynthetic mesh reinforcement and patients undergoing standard abdominal wall closure.

Time frame
Intraoperatively
2

Readmission and reoperation rates

The rates of unplanned hospital readmission and reoperation after the index surgery will be assessed and compared between treatment groups.

Time frame
Within 30 days after surgery
3

30-day postoperative morbidity and mortality

Thirty-day postoperative morbidity and mortality will be assessed, including the occurrence of postoperative complications and death within 30 days after the index surgery. Postoperative complications will be recorded and compared between treatment groups.

Time frame
Within 30 days after surgery
4

Postoperative pain assessed by Visual Analogue Scale (VAS)

Postoperative pain will be assessed using the Visual Analog Scale (VAS), a 0-10 scale, where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores will be compared between treatment groups.

Time frame
Postoperative days 1, 3, and 5

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Rome Tor Vergata

Lead sponsor

Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

Collaborator

San Filippo Neri General Hospital

Collaborator

San Giovanni Addolorata Hospital

Collaborator

Santa Maria della Pieta Hospital - Nola

Collaborator

Buccheri La Ferla Hospital, Palermo

Collaborator

Cardarelli Hospital, Naples, Italy

Collaborator

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator

This trial is not recruiting at the moment. You can still explore other options: